Supernus to Present at Cowen and Company Healthcare Conference in March

  Supernus to Present at Cowen and Company Healthcare Conference in March

Cowen and Company 34th Annual Healthcare Conference

Business Wire

ROCKVILLE, Md. -- February 20, 2014

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical
company, today announced that the Company’s management will provide a business
update on the Company at the Cowen and Company Healthcare Conference.

          
                      Presentation Date: Monday, March 3
                      Time: 1:30pm ET
                      Place: The Boston Marriott Copley Place Hotel, Boston,
                      MA
                      

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Contact:

Supernus Pharmaceuticals, Inc.
Jack A. Khattar, President and CEO
or
Gregory S. Patrick, Vice President and CFO
301-838-2591
or
Investor Contact:
Cockrell Group, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
 
Press spacebar to pause and continue. Press esc to stop.